



62946_Auto_Edited.docx

Quotes Excluded
Bibliography Excluded27%
SIMILAR

40

Name of Journal: *World Journal of Gastrointestinal Pharmacology and Therapeutics***Manuscript NO:** 62946**Manuscript Type:** REVIEW**Advances in treatment and prevention of hepatitis B**

Recent advances in chronic Hepatitis B

Niraj James Shah, Aloysius Mark Madhok, Neil Rohit Sharma, Kumar Pallav

Match Overview

1	Internet 254 words crawled on 30-Nov-2020 www.cdc.gov	3%
2	Internet 129 words crawled on 07-Nov-2020 onlinelibrary.wiley.com	2%
3	Internet 113 words crawled on 24-Sep-2020 apps.who.int	1%
4	Internet 91 words crawled on 11-Apr-2021 www.gutnliver.org	1%
5	Internet 80 words crawled on 29-Apr-2016 francais.cdc.gov	1%
6	Internet 78 words crawled on 03-May-2020 www.ncbi.nlm.nih.gov	1%

Crossref 71 words

激活 Windows
转到“设置”以激活 Windows。


Text-Only Report



ALL

IMAGES

VIDEOS

 Add the Give with Bing extension >

21,400,000 Results

Any time ▾

Hepatitis B Virus: Advances in Prevention, Diagnosis, and ...

<https://pubmed.ncbi.nlm.nih.gov/32102898>

Hepatitis C virus (HCV) and hepatitis B virus (HBV) are the leading causes of liver cancer and overall mortality globally, surpassing malaria and tuberculosis. Linkage to care is estimated to be very poor both in developing countries and in high-income countries, such as the United States, countries in Western Europe, and Japan.

Cited by: 22

Author: Mindie H. Nguyen, Grace Wong, Edward ...

Publish Year: 2020

Advances in hepatitis B therapeutics

<https://pubmed.ncbi.nlm.nih.gov/33117536>

Globally, chronic hepatitis B is the leading cause of **hepatocellular carcinoma**, which represents the third cause of cancer mortality, accounting for nearly 1 million annual deaths. Current oral nucleos(t)ide **therapy** with tenofovir or entecavir suppresses serum HBV-DNA in most treated patients, but rarely is accompanied by HBsAg loss. Thus, **treatment** has to be given lifelong to **prevent** viral rebound.

Cited by: 2

Author: Vicente Soriano, Pablo Barreiro, Edward ...

Publish Year: 2020

Recent advances in prevention of hepatitis B recurrence

See results for

Hepatitis C virus (Rna Viru)

The hepatitis C virus is a small, enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. The h...



Search Tools

[Turn off Hover Translation \(关闭取词\)](#)

激活 Windows

转到“设置”以激活 Windows。

[ALL](#)
[IMAGES](#)
[VIDEOS](#)
[MAPS](#)
[NEWS](#)
[SHOPPING](#)

10,400,000 Results Any time ▾

Hepatitis B Virus: Advances in Prevention, Diagnosis, and ...

<https://pubmed.ncbi.nlm.nih.gov/32102898>

Hepatitis C virus (HCV) and hepatitis B virus (HBV) are the leading causes of liver cancer and overall mortality globally, surpassing malaria and tuberculosis. Linkage to care is estimated to be very poor both in developing countries and in high-income countries, such as the United States, countries in Western Europe, and Japan.

Cited by: 22 Author: Mindie H. Nguyen, Grace Wong, Edward Ga...
Publish Year: 2020

Advances in hepatitis B therapeutics

<https://pubmed.ncbi.nlm.nih.gov/33117536>

Globally, chronic hepatitis B is the leading cause of hepatocellular carcinoma, which represents the third cause of cancer mortality, accounting for nearly 1 million annual deaths. Current oral nucleos(t)ide therapy with tenofovir or entecavir suppresses serum HBV-DNA in most treated patients, but rarely is accompanied by HBsAg loss. Thus, treatment has to be given lifelong to prevent viral rebound.

Cited by: 2 Author: Vicente Soriano, Pablo Barreiro, Edward R. ...
Publish Year: 2020

Therapeutic advances in the management of chronic ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3697843>

Prevention of hepatitis B. There are two important preventative measures that reduce the spread of HBV: prevention of transmission and immunization. In endemic areas these are in effect the same goal as the main mode of transmission is vertical.

Cited by: 5 Author: Johanne Brooks, William Gelson, Simon M....
Publish Year: 2013

Recent advances in prevention of hepatitis B recurrence ...

<https://www.ncbi.nlm.nih.gov/pubmed/25624716>

Jan 21, 2015 · first-line monotherapies for the treatment of chronic hepatitis B infection. These antiviral medicines have replaced lamivudine as the first choice in the prevention of HBV recurrence after liver transplantation. Various therapies that are composed of entecavir, tenofovir, and lamivudine ...

Cited by: 9 Author: Zhi-Feng Xi, Qiang Xia
Publish Year: 2015

Hepatitis B

Medical Condition



A serious infection of the liver caused by hepatitis B virus (HBV).

- Common (More than 200,000 cases per year in US)
- Transmitted through direct contact
- Usually preventable by vaccine
- Often requires lab test or imaging
- Treatments can help manage condition, no known cure
- Can be lifelong

An infection caused by HBV that affects the liver. Spreading through exposure to virus by blood, semen, saliva, or vaginal fluids, the virus is transmitted through unsafe sexual practices and from an infected mother to her child. Symptoms include loss of appetite, nausea, body aches and fever progressing to jaundice. Chronic form of the infection is not curable, but HBV is preventable by vaccination.

Symptoms